LOS ANGELES--(BUSINESS WIRE)--June 14, 2006--Cougar Biotechnology, Inc., a publicly held biotechnology company, today announced the appointment of Michael S. Richman to the Company’s Board of Directors. Mr. Richman is currently the Executive Vice President and Chief Operating Officer of Macrogenics, Inc, a privately held biotechnology company engaged in the development of immune-based products including monoclonal antibodies to treat patients with cancer, autoimmune disorders, allergy, or infectious diseases and vaccines to prevent infections in healthy individuals.
